Removes restrictions of three-cycle coverage for in vitro fertilization; mandates individual insurance coverage of in vitro.
This bill expands New York insurance coverage for infertility treatment, with a particular focus on in vitro fertilization (IVF). It removes the current statutory limit that requires large group policies and contracts to cover only three IVF cycles, replacing that cap with a broader mandate for coverage of IVF used in the treatment of infertility. The bill also updates related insurance provisions governing hospital, medical, and prescription drug coverage so that infertility diagnosis and treatment are covered more comprehensively under large group and individual policies.
In addition to IVF coverage, the bill strengthens existing infertility-related protections by requiring coverage for diagnostic tests and procedures needed to determine infertility, medically necessary procedures that correct malformation, disease, or dysfunction causing infertility, and FDA-approved prescription drugs used in infertility treatment. It also requires coverage for standard fertility preservation services when a medical treatment may cause iatrogenic infertility, and it adds a retail-pharmacy parity rule for prescription fertility drugs when a plan uses mail-order or other non-retail pharmacy networks. The bill defines infertility and iatrogenic infertility, preserves existing exclusions for certain categories such as elective sterilization reversal, sex change procedures, cloning, and experimental treatments, and sets an effective date of January 1, 2026 for policies and contracts issued or renewed on or after that date.
The bill would amend multiple sections of the New York Insurance Law, including provisions applicable to large group policies, large group contracts, and individual hospital/medical coverage. Its main legal effect is to eliminate the three-cycle limitation for IVF coverage in large group plans and to require broader coverage of infertility diagnosis and treatment, including IVF, fertility preservation, and related prescription drugs, subject to deductibles and coinsurance consistent with other benefits. It would also impose nondiscrimination requirements in infertility coverage and create a pharmacy access rule for fertility medications. Insurers, employers offering covered plans, and policyholders would be directly affected, while collective bargaining agreements are expressly preserved from being superseded by the retail-pharmacy provision.
The bill appears to be generally supportive of expanded fertility coverage, with the caption and text reflecting a clear policy choice to broaden access to IVF and related infertility services. Because there are no committee transcripts or recorded votes provided, there is no documented debate in the supplied materials, but the structure of the bill suggests a pro-coverage, patient-access orientation. The measure is framed as an expansion of benefits rather than a restriction or cost-control bill.
The main points of potential contention are likely to be cost, insurance premium impacts, and the scope of mandated benefits, especially the removal of the three-cycle IVF cap and the extension of coverage into individual policies and fertility preservation services. Insurers and employers may object to the broader mandate and the associated reimbursement obligations, while patient advocates and infertility patients would likely support the expansion. Another possible area of dispute is the interaction with collective bargaining agreements, since the bill expressly states that the pharmacy-parity provision does not supersede such agreements. The bill also preserves exclusions for experimental procedures and certain non-infertility-related treatments, which may limit debate on some boundaries of coverage but could still raise questions about implementation and regulatory definitions.